Drug intelligence / Profile preview

methamphetamine

Development stage
Approved
Lead developer
Abbott
Modality
Small Molecules
Administration
Oral, Inhalation, Intranasal, Intravenous
01

Overview

Methamphetamine is a synthetic, highly addictive central nervous system stimulant belonging to the phenethylamine class. It is structurally related to amphetamine but has greater potency and longer-lasting effects. Methamphetamine increases synaptic concentrations of dopamine, norepinephrine, and serotonin by promoting their release and blocking reuptake in the brain. This results in increased alertness, energy, euphoria, decreased appetite, and enhanced focus. The drug is FDA-approved for the treatment of attention deficit hyperactivity disorder (ADHD) and short-term management of obesity under the brand name Desoxyn; however, most use worldwide is illicit. Methamphetamine can be administered orally (tablet), smoked (crystal form), snorted (powder), or injected (solution). Adverse effects include high addiction potential, cardiovascular complications such as hypertension and arrhythmias, neurotoxicity leading to cognitive deficits with chronic use, psychiatric symptoms including paranoia or psychosis, "meth mouth" due to severe dental decay, insomnia, agitation, hyperthermia at high doses which may be fatal[1][2][4][6][7].

Brand names
DesoxynDesoxyn Gradumet
Other names
crystal methTinaiceBatuBikers CoffeeBlack BeautiesChalkChicken FeedCrankGlassGo-FastHiroponMethlies QuickPoor Man's CocaineShabuShardsSpeedStove TopTrashTweakUppersVentanaVidrioYabaYellow Barn
02

Targets

VMAT2 (Vesicular monoamine transporter 2)TAAR1 (Trace amine-associated receptor 1)NET (Norepinephrine Transporter)DAT (Dopamine plasma membrane transport protein)SERT (Sodium-dependent serotonin transporter)

Beyond the preview

Go deeper on methamphetamine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on methamphetamine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call